SCHEMBL2817569

SCHEMBL2817569

COC(=O)C1CC(N(Cc2ccccc2)C(=O)OCC(Cl)(Cl)Cl)CN1C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.43
CETP P11597 2/20 0.42
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
KLK5 Q9Y337 1/20 0.38
AGTR2 P50052 1/20 0.37
NR1H2 P55055 3/20 0.36
NR1H3 Q13133 3/20 0.36
KLK7 P49862 1/20 0.36
PTPN1 P18031 1/20 0.36
P2RX3 P56373 1/20 0.36
AKT1 P31749 1/20 0.36
PTPRB P23467 1/20 0.36
PTPN11 Q06124 1/20 0.36
HTRA1 Q92743 1/20 0.35
UCHL1 P09936 1/20 0.35
MCL1 Q07820 1/20 0.35
FKBP1A P62942 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13841900 1.00 HSD11B1 (0.43) HSD11B1CETPJAK2JAK1KLK5
SCHEMBL2820222 0.92 HSD11B1 (0.45) HSD11B1CETPJAK2JAK1AGTR2
SCHEMBL13841899 0.92 HSD11B1 (0.45) HSD11B1CETPJAK2JAK1AGTR2
SCHEMBL29929920 0.91 P2RX3 (0.40) HSD11B1CETPPTPN1P2RX3
SCHEMBL20475113 0.85 HSD11B1 (0.38) HSD11B1CETPJAK2JAK1
SCHEMBL20475134 0.84 HDAC8 (0.44) HSD11B1PTPN1
SCHEMBL2818340 0.83 HTR2A (0.44)
SCHEMBL25181066 0.83 JAK2 (0.57) HSD11B1CETPJAK2JAK1KLK5
SCHEMBL30638156 0.82 HSD11B1 (0.46) HSD11B1CETPJAK2JAK1KLK5
SCHEMBL12479425 0.80 NR1H2 (0.34) HSD11B1CETPNR1H2NR1H3PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155672-B1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-10-27 EP disclosed
EP-2155672-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-02-24 EP disclosed
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed
WO-2008148689-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 HSD11B1 2349/4885CETP 4629/4885JAK2 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.